Guest: Caroline Loew, Ph.D., President & CEO, Glympse Bio
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership Clarivate, speaks with Dr. Caroline Loew, President and CEO from Glympse Bio. They discuss the biotech’s focus on both disease detection and response to treatment using bioengineered sensors, starting with NASH. Dr. Loew also shares career advice for moving from pharma to biotech and how she pivoted the company’s narrative during a funding round at the bottom of the pandemic-related stock market crash. Learn more in the full episode.
About our guest
Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered and integrated teams. She has broad experience integrating science, business and the clinic to deliver differentiated value to patients.
Most recently, she was Vice President, Head R&D Strategy and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning inmmune-oncology, immunoscience, fibrosis and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory and drug development.
An organic chemist by training, Caroline studied as an undergraduate and postgraduate at Imperial College, London.
About our host
Mike Ward serves as Global Head of Thought Leadership at Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.